Insider trade

10% owner sold ~$21.4M of BLFS shares in the open market

Traded Oct 15, 2025 · Filed Oct 17, 2025

Why it stands out

A 10% owner of BioLife Solutions sold $21.4M of BioLife Solutions shares. The filing does not indicate a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

10% ownerIndirect holding$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$21,410,325

Shares × reported transaction price

Timing vs results

69 days after results of Aug 7, 2025, 22 days before results of Nov 6, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.7%	+2.1%	−1.4%
30 days	−12.5%	−1.3%	−11.2%
90 days	−11.1%	+0.9%	−12.1%
180 days	−20.4%	+5.6%	−25.9%

Past results only. Not a forecast.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $28.50 to $28.8354. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.